Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

1.

Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group.

Can J Kidney Health Dis. 2015 Aug 18;2:33. doi: 10.1186/s40697-015-0066-5. eCollection 2015.

2.

THE EFFECT OF EXIT-SITE ANTIBACTERIAL HONEY VERSUS NASAL MUPIROCIN PROPHYLAXIS ON THE MICROBIOLOGY AND OUTCOMES OF PERITONEAL DIALYSIS-ASSOCIATED PERITONITIS AND EXIT-SITE INFECTIONS: A SUB-STUDY OF THE HONEYPOT TRIAL.

Zhang L, Badve SV, Pascoe EM, Beller EM, Cass A, Clark C, Zoysa JD, Isbel NM, McTaggart S, Morrish AT, Playford G, Scaria A, Snelling PL, Vergara LA, Hawley CM, Johnson DW.

Perit Dial Int. 2015 Jul 29. pii: pdi.2014.00206. [Epub ahead of print]

PMID:
26224790
3.

Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Seong HL, Meng OL, Irish AB; FAVOURED study team.

Nephrology (Carlton). 2015 Jul 24. doi: 10.1111/nep.12573. [Epub ahead of print]

PMID:
26205903
4.

Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW.

Nephrol Dial Transplant. 2015 Jul 11. pii: gfv269. [Epub ahead of print] Review.

PMID:
26163881
5.

The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.

Viecelli AK, Pascoe E, Polkinghorne KR, Hawley C, Paul-Brent PA, Badve SV, Cass A, Heritier S, Kerr PG, Mori TA, Robertson A, Seong HL, Irish AB; FAVOURED study team.

BMC Nephrol. 2015 Jun 27;16:89. doi: 10.1186/s12882-015-0089-2.

6.

The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.

Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group.

Redox Rep. 2015 Jun 17. [Epub ahead of print]

PMID:
26083328
7.

Daily home hemodialysis: balancing cardiovascular benefits with infectious harms.

Nadeau-Fredette AC, Badve SV, Johnson DW.

Am J Kidney Dis. 2015 Jan;65(1):6-8. doi: 10.1053/j.ajkd.2014.08.012. No abstract available.

PMID:
25523799
8.

The association between body mass index and mortality in incident dialysis patients.

Badve SV, Paul SK, Klein K, Clayton PA, Hawley CM, Brown FG, Boudville N, Polkinghorne KR, McDonald SP, Johnson DW.

PLoS One. 2014 Dec 16;9(12):e114897. doi: 10.1371/journal.pone.0114897. eCollection 2014.

9.

The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study.

Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Hawley CM, Isbel NM, Krum H, Pascoe EM, Tonkin AM, Vergara LA, Perkovic V; BLOCADE Study Collaborative Group.

Nephrology (Carlton). 2015 Mar;20(3):140-7. doi: 10.1111/nep.12362.

PMID:
25382452
10.

A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.

Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group.

Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020. Epub 2014 Aug 10.

PMID:
25115616
11.

End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.

Mallett A, Tang W, Clayton PA, Stevenson S, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Campbell SB, Johnson DW.

Nephrol Dial Transplant. 2014 Dec;29(12):2277-86. doi: 10.1093/ndt/gfu254. Epub 2014 Jul 24.

PMID:
25061124
12.

A nephrology guide to reading and using systematic reviews of randomized trials.

Badve SV, Palmer SC, Johnson DW, Strippoli GF.

Nephrol Dial Transplant. 2015 Jun;30(6):878-84. doi: 10.1093/ndt/gfu222. Epub 2014 Jun 23. Review.

PMID:
24957810
13.

Biocompatible dialysis fluids for peritoneal dialysis.

Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ.

Cochrane Database Syst Rev. 2014 Mar 27;3:CD007554. doi: 10.1002/14651858.CD007554.pub2. Review.

PMID:
24671928
14.

The association between peritoneal dialysis modality and peritonitis.

Lan PG, Johnson DW, McDonald SP, Boudville N, Borlace M, Badve SV, Sud K, Clayton PA.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1091-7. doi: 10.2215/CJN.09730913. Epub 2014 Mar 13.

15.

Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis.

Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, Clayton P, Johnson DW.

Nephrol Dial Transplant. 2014 Oct;29(10):1940-7. doi: 10.1093/ndt/gfu050. Epub 2014 Mar 3.

PMID:
24596083
16.

The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.

Stevenson S, Tang W, Cho Y, Mudge DW, Hawley CM, Badve SV, Johnson DW.

Perit Dial Int. 2015 Mar-Apr;35(2):222-8. doi: 10.3747/pdi.2013.00156. Epub 2014 Mar 1.

PMID:
24584597
17.

Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients.

Tang W, Grace B, McDonald SP, Hawley CM, Badve SV, Boudville NC, Brown FG, Clayton PA, Johnson DW.

Perit Dial Int. 2015 7-8;35(4):450-459. Epub 2014 Feb 4.

PMID:
24497587
18.

Chronic kidney disease: haemodialysis catheter care in practice.

Badve SV, Johnson DW.

Nat Rev Nephrol. 2014 Mar;10(3):131-3. doi: 10.1038/nrneph.2014.3. Epub 2014 Jan 21. Review.

PMID:
24445741
19.

The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis.

Tang W, Cho Y, Hawley CM, Badve SV, Johnson DW.

Perit Dial Int. 2014 Mar-Apr;34(2):219-26. doi: 10.3747/pdi.2012.00318. Epub 2014 Jan 2.

20.

Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.

Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM; HONEYPOT Study Collaborative Group.

Lancet Infect Dis. 2014 Jan;14(1):23-30. doi: 10.1016/S1473-3099(13)70258-5. Epub 2013 Oct 10.

PMID:
24119840
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk